Nutrients · 2026
Reframing Nutraceuticals in Knee Osteoarthritis with Sarcopenia: A Muscle-Joint-Centered Narrative Review.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Park Dojoon, Koh Hae-Seok, Choi Youn-Ho, Moon Jeong Wook, Park Ilkyu
Аннотация
BACKGROUND/OBJECTIVES: Knee osteoarthritis (KOA) is increasingly recognized as a function-limiting condition in which pain, neuromuscular impairment, and reduced physical activity interact with sarcopenic vulnerability to accelerate functional decline. This review reappraises commonly used oral nutraceuticals through a muscle-joint framework and examines whether they can be conservatively positioned as adjuncts that reduce symptom-related barriers to exercise-based care rather than as disease-modifying therapies.
METHODS: This review was conducted as a structured narrative synthesis informed by SANRA principles, using a structured and transparent search process and dual-independent study selection, without quantitative meta-analysis or formal certainty-of-evidence grading. PubMed/MEDLINE, Embase, and the Cochrane Library were searched for English-language studies published from January 2000 to March 2026, supplemented by reference screening of key reviews and international guidelines.
RESULTS: Mechanistic and clinical evidence supports a plausible pathway linking KOA pain, arthrogenic muscle inhibition, reduced loading, physical inactivity, and sarcopenic vulnerability. Across glucosamine/chondroitin, collagen peptides, omega-3 fatty acids, curcumin, and Boswellia, symptomatic benefits were modest, heterogeneous, and formulation-dependent, with no consistent evidence of structural disease modification. Direct evidence that nutraceuticals improve exercise adherence or long-term physical activity remains limited; however, selected exercise-integrated or function-oriented studies show participation-relevant signals in gait speed, activity volume, and performance-based outcomes.
CONCLUSIONS: Nutraceuticals should be interpreted as optional, time-limited adjuncts within exercise-centered KOA management. Their potential value lies in modest symptom support that may facilitate rehabilitation participation in selected patients, not in stand-alone treatment of KOA or sarcopenia.
METHODS: This review was conducted as a structured narrative synthesis informed by SANRA principles, using a structured and transparent search process and dual-independent study selection, without quantitative meta-analysis or formal certainty-of-evidence grading. PubMed/MEDLINE, Embase, and the Cochrane Library were searched for English-language studies published from January 2000 to March 2026, supplemented by reference screening of key reviews and international guidelines.
RESULTS: Mechanistic and clinical evidence supports a plausible pathway linking KOA pain, arthrogenic muscle inhibition, reduced loading, physical inactivity, and sarcopenic vulnerability. Across glucosamine/chondroitin, collagen peptides, omega-3 fatty acids, curcumin, and Boswellia, symptomatic benefits were modest, heterogeneous, and formulation-dependent, with no consistent evidence of structural disease modification. Direct evidence that nutraceuticals improve exercise adherence or long-term physical activity remains limited; however, selected exercise-integrated or function-oriented studies show participation-relevant signals in gait speed, activity volume, and performance-based outcomes.
CONCLUSIONS: Nutraceuticals should be interpreted as optional, time-limited adjuncts within exercise-centered KOA management. Their potential value lies in modest symptom support that may facilitate rehabilitation participation in selected patients, not in stand-alone treatment of KOA or sarcopenia.